We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$450M
AUM Growth
+$20.6M
Cap. Flow
+$23.6M
Cap. Flow %
5.23%
Top 10 Hldgs %
53.49%
Holding
51
New
15
Increased
13
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$16M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$15.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
4
PASG icon
Passage Bio
PASG
+$12.4M
5
RNAM
Avidity Biosciences
RNAM
+$11.9M

Top Sells

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$29.4M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$16.1M
3
UTHR icon
United Therapeutics
UTHR
+$16M
4
BIIB icon
Biogen
BIIB
+$13.4M
5
SAGE
Sage Therapeutics
SAGE
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
$49.3M 10.96%
530,670
– –
EXEL icon
2
Exelixis
EXEL
$13.3B
$32M 7.11%
1,750,000
+225,000
+15% +$4.31M
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.06B
$29.7M 6.59%
950,000
+250,000
+36% +$7.47M
TVTX icon
4
Travere Therapeutics
TVTX
$5.2B
$24.8M 5.52%
800,000
+175,000
+28% +$4.93M
ANAB icon
5
AnaptysBio
ANAB
$1.58B
$20.6M 4.57%
592,250
+42,705
+8% +$1.35M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$121B
$18.7M 4.15%
85,000
– –
BCAB icon
7
BioAtla
BCAB
$5.46M
$17M 3.77%
17,286
+406
+2% +$519K
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$16.5M 3.67%
+300,000
New +$15.7M
RLMD icon
9
Relmada Therapeutics
RLMD
$557M
$16.2M 3.59%
+717,320
New +$16M
MGNX icon
10
MacroGenics
MGNX
$235M
$16.1M 3.57%
1,000,000
– –
CYTK icon
11
Cytokinetics
CYTK
$10.5B
$16M 3.54%
350,000
-41,429
-11% -$1.6M
TCDA
12
DELISTED
Tricida, Inc. Common Stock
TCDA
$13.4M 2.97%
1,400,000
-574,000
-29% -$3.7M
RIGL icon
13
Rigel Pharmaceuticals
RIGL
$681M
$13.3M 2.94%
500,000
+302,000
+153% +$9.11M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.57B
$13.1M 2.91%
+145,405
New +$12.4M
BCYC
15
Bicycle Therapeutics
BCYC
$269M
$12.2M 2.7%
+200,000
New +$11M
PCVX icon
16
Vaxcyte
PCVX
$7.81B
$11.9M 2.64%
500,000
+401,939
+410% +$9.35M
RNAM
17
DELISTED
Avidity Biosciences
RNAM
$11.9M 2.64%
+500,000
New +$11.9M
ACRS icon
18
Aclaris Therapeutics
ACRS
$726M
$11.6M 2.58%
800,000
+300,000
+60% +$4.55M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$340M
$10.9M 2.43%
500,526
-264,474
-35% -$7.21M
SLN
20
Silence Therapeutics
SLN
$495M
$10.6M 2.36%
+444,443
New +$10.3M
DYN icon
21
Dyne Therapeutics
DYN
$4.7B
$10M 2.23%
845,000
+100,000
+13% +$1.41M
PASG icon
22
Passage Bio
PASG
$14.4M
$9.64M 2.14%
+75,905
New +$12.4M
PRQR icon
23
ProQR Therapeutics
PRQR
$243M
$8.98M 2%
1,121,122
+1,090,786
+3,596% +$8.31M
URGN icon
24
UroGen Pharma
URGN
$1.86B
$8.31M 1.85%
873,424
+123,424
+16% +$1.74M
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$6.36M 1.41%
+390,041
New +$5.55M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Great Point Partners held 51 positions worth $450M, up 4.8% from $429M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Great Point Partners deployed $23.6M of net new capital in Q4 2021, opening 15 new positions and adding to 13 existing holdings. Its largest new stake was Relmada Therapeutics: 717,320 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $7.21M trimmed.

  • Great Point Partners's largest Q4 2021 buy was Relmada Therapeutics: 717,320 shares worth $16.2M.
  • Great Point Partners added most to Vaxcyte in Q4 2021, an estimated $9.35M increase.
  • Great Point Partners's biggest Q4 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $7.21M.
  • Great Point Partners fully exited Kadmon Holdings, Inc. in Q4 2021, selling an estimated $29.4M.
  • Great Point Partners's ten largest holdings make up 53% of its $450M portfolio in Q4 2021.
  • Great Point Partners opened 15 new positions and closed 15 in Q4 2021.
  • Great Point Partners's portfolio value rose 4.8% quarter-over-quarter to $450M.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.